Mignot E, Bowersox S S, Maddaluno J, Dement W, Ciaranello R
Sleep Research Center, Stanford University School of Medicine, Palo Alto, CA 94304.
Brain Res. 1989 May 1;486(1):56-66. doi: 10.1016/0006-8993(89)91277-8.
Two classes of alpha 1 adrenoceptors were identified in canine brain and liver using conventional radioligand binding methods. Scatchard plots of specific [3H]prazosin binding to brain and liver membranes prepared from 100-150-day-old Doberman pinscher dogs were consistently curvilinear and best fit a two-site binding model (frontal cortex, Kd1 = 57.7 +/- 10.0 pM, Bmax1 = 64.6 +/- 17.1 fmol/mg protein, Kd2 = 1.5 +/- 0.5 nM, Bmax2 = 159 +/- 37.6 fmol/mg protein; liver, Kd1 = 82.6 +/- 36 pM, Bmax1 = 7.0 +/- 5.1 fmol/mg protein, Kd2 = 0.8 +/- 0.2 nM, Bmax2 = 62.1 +/- 8.7 fmol/mg protein). Kinetically derived affinity constants from association and dissociation experiments agreed with those obtained by Scatchard analyses of equilibrium binding data. Binding sites were saturable, heat labile, bound ligand reversibly, and appeared to be appropriately distributed in relation to endogenous catecholamine. [3H]Prazosin also bound with high affinity to two classes of binding site in porcine and bovine brain membrane but [3H]prazosin binding in monkey and rat brain was best described by a single-site binding model. Affinities obtained were in between values obtained for high and low affinity Kds in the other species. Competitions for [3H]prazosin binding sites in canine frontal cortex were conducted with the following antagonists: WB-4101, corynanthine, phentolamine, benoxathian, phenoxybenzamine, chlorethylclonidine, thymoxamine, prazosin, yohimbine and agonists: methoxamine, (-)-norepinephrine, and clonidine. All ligands but prazosin, norepinephrine and clonidine competed for specific [3H]prazosin binding in a statistically significant biphasic manner. Benoxathian and WB-4101 displayed the highest affinities (benoxathian: Ki1 = 0.26 nM, WB-4101: Ki1 = 0.20 nM) and selectivity (high affinity/low affinity: benoxathian = 1640, WB-4101 = 13204) for the high affinity [3H]prazosin binding site; chlorethylclonidine had highest affinity (Ki2 = 91 nM) and selectivity (low affinity/high affinity = 405) for the lower affinity [3H]prazosin binding site. As defined, the two sites were similar to the alpha 1a and alpha 1b recently described in the rat and rabbit. A noticeable difference was that the subtypes described in dog brain had a 30-fold difference in affinity for prazosin.
采用传统放射性配体结合方法,在犬脑和肝脏中鉴定出两类α1肾上腺素能受体。用[³H]哌唑嗪特异性结合100 - 150日龄杜宾犬制备的脑和肝膜的Scatchard图始终呈曲线,最适合双位点结合模型(额叶皮质,Kd1 = 57.7 ± 10.0 pM,Bmax1 = 64.6 ± 17.1 fmol/mg蛋白质,Kd2 = 1.5 ± 0.5 nM,Bmax2 = 159 ± 37.6 fmol/mg蛋白质;肝脏,Kd1 = 82.6 ± 36 pM,Bmax1 = 7.0 ± 5.1 fmol/mg蛋白质,Kd2 = 0.8 ± 0.2 nM,Bmax2 = 62.1 ± 8.7 fmol/mg蛋白质)。结合和解离实验动力学推导的亲和常数与平衡结合数据的Scatchard分析得到的结果一致。结合位点是可饱和的、热不稳定的、可逆结合配体,并且相对于内源性儿茶酚胺似乎分布适当。[³H]哌唑嗪也与猪和牛脑膜中的两类结合位点具有高亲和力结合,但猴和大鼠脑中的[³H]哌唑嗪结合最好用单位点结合模型描述。获得的亲和力介于其他物种高亲和力和低亲和力Kd值之间。用以下拮抗剂进行犬额叶皮质中[³H]哌唑嗪结合位点的竞争实验:WB - 4101、育亨宾碱、酚妥拉明、贝诺沙嗪、酚苄明、氯乙可乐定、噻吗洛尔、哌唑嗪、育亨宾和激动剂:甲氧明、(-)-去甲肾上腺素和可乐定。除哌唑嗪﹑去甲肾上腺素和可乐定外,所有配体均以具有统计学意义的双相方式竞争特异性[³H]哌唑嗪结合。贝诺沙嗪和WB - 4101对高亲和力[³H]哌唑嗪结合位点显示出最高亲和力(贝诺沙嗪:Ki1 = 0.26 nM,WB - 4101:Ki1 = 0.20 nM)和选择性(高亲和力/低亲和力:贝诺沙嗪 = 1640,WB - 4101 = ********);氯乙可乐定对低亲和力[³H]哌唑嗪结合位点具有最高亲和力(Ki2 = 91 nM)和选择性(低亲和力/高亲和力 = 405)。如所定义,这两个位点类似于最近在大鼠和兔子中描述的α1a和α1b。一个明显的差异是犬脑中描述的亚型对哌唑嗪的亲和力相差30倍。 (注:原文中WB - 4101的高亲和力/低亲和力比值处数据缺失,译文保留原文格式)